Il-15 Superagonist and Dinutuximab significantly Enhance Expanded Natural Killer Cell Activity Against Gd2(+) Pediatric Solid Tumors (ST)
Author Type(s)
Faculty, Student
Document Type
Abstract
Publication Date
6-2019
Journal Title
Pediatric Blood & Cancer
Department
Pediatrics
Second Department
Pharmacology
Recommended Citation
Chu, Y., Nayyar, G., Rosenblum, J., Lyngdoh, J., Cao, J., Jeng, E., Alter, S., Rhode, P. R., Amar, S., Lee, D. A., Wong, H. C., Lee, J. H., & Cairo, M. S. (2019). Il-15 Superagonist and Dinutuximab significantly Enhance Expanded Natural Killer Cell Activity Against Gd2(+) Pediatric Solid Tumors (ST). Pediatric Blood & Cancer, 66 (Suppl. 2), 1026. Retrieved from https://touroscholar.touro.edu/nymc_fac_abstracts/275
COinS